Malignant tumor
Conditions
Interventions
Sponsors
Changzhou Cancer (Fourth People's) Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age between 18 and 75 years old, gender not limited. 2.Malignant tumor patients requiring treatment with apatinib mesylate. 3.Patients who have not used apatinib mesylate tablets within the past week. 4.Patients who voluntary signing of informed consent form and have good treatment compliance.
Exclusion criteria
Exclusion criteria: 1.Patients who have developed gastrointestinal diseases such as gastric ulcers, constipation, intestinal obstruction, and diarrhea in the past month and are currently using relevant medications for treatment. 2.Patients currently taking proton pump inhibitors and other antacids. 3.Patients with concurrent other chronic diseases that require long-term medication, and the researchers believe that patients who are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of apatinib mesylate in human blood; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetic parameters; | — |
Countries
China
Contacts
Public ContactGuangzhao He
Changzhou Cancer (Fourth People's) Hospital
Outcome results
None listed